FI3395423T3 - Vuotaneen affiniteettipuhdistusligandin poistaminen - Google Patents

Vuotaneen affiniteettipuhdistusligandin poistaminen Download PDF

Info

Publication number
FI3395423T3
FI3395423T3 FIEP18168494.5T FI18168494T FI3395423T3 FI 3395423 T3 FI3395423 T3 FI 3395423T3 FI 18168494 T FI18168494 T FI 18168494T FI 3395423 T3 FI3395423 T3 FI 3395423T3
Authority
FI
Finland
Prior art keywords
protein
chromatography medium
anion exchange
recombinant protein
exchange matrix
Prior art date
Application number
FIEP18168494.5T
Other languages
English (en)
Finnish (fi)
Inventor
Samuel Ray Trejo
Robert Perry Brake
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50424772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3395423(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of FI3395423T3 publication Critical patent/FI3395423T3/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/18Ion-exchange chromatography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361Ion-exchange
    • B01D15/363Anion-exchange
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804Affinity chromatography
    • B01D15/3809Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/10Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FIEP18168494.5T 2013-03-14 2014-03-11 Vuotaneen affiniteettipuhdistusligandin poistaminen FI3395423T3 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361785038P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
FI3395423T3 true FI3395423T3 (fi) 2023-11-02

Family

ID=50424772

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP18168494.5T FI3395423T3 (fi) 2013-03-14 2014-03-11 Vuotaneen affiniteettipuhdistusligandin poistaminen

Country Status (17)

Country Link
US (3) US20160024144A1 (https=)
EP (3) EP3395423B1 (https=)
JP (1) JP6457479B2 (https=)
AU (1) AU2014240596B2 (https=)
CA (1) CA2904411A1 (https=)
CY (1) CY1120353T1 (https=)
DK (2) DK3395423T3 (https=)
ES (2) ES2964601T3 (https=)
FI (1) FI3395423T3 (https=)
HU (2) HUE064450T2 (https=)
LT (2) LT3395423T (https=)
MX (2) MX391507B (https=)
PL (2) PL3395423T3 (https=)
PT (2) PT3395423T (https=)
SI (2) SI3395423T1 (https=)
TR (1) TR201809050T4 (https=)
WO (1) WO2014159441A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3395423B1 (en) 2013-03-14 2023-09-20 Amgen Inc. Removal of leaked affinity purification ligand
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
AU2015273049B2 (en) * 2014-06-13 2019-11-14 Lupin Limited Process for the purification of TNFR:Fc fusion protein
CN105214341B (zh) * 2015-09-17 2017-12-15 广州康盛生物科技有限公司 组合型吸附柱及其制备方法
WO2017168296A1 (en) * 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
US12516102B1 (en) 2017-02-09 2026-01-06 Bracco Suisse Sa Process for the purification of soluble PSGL-1 protein variants
CN118047854B (zh) * 2024-02-26 2024-08-02 武汉鹰达生物科技有限公司 一种人载脂蛋白a-i的分离纯化方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
DE3811042A1 (de) 1988-03-31 1989-10-19 Merck Patent Gmbh Ionenaustauscher
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
DE4333821A1 (de) 1993-10-04 1995-04-06 Merck Patent Gmbh Ionenaustauscher
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
DE19501726A1 (de) 1995-01-20 1996-07-25 Merck Patent Gmbh Polymerisationsfähige Derivate von Polyamiden
AU708239B2 (en) 1995-06-29 1999-07-29 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
WO1997049754A1 (de) 1996-06-21 1997-12-31 Merck Patent Gmbh Polymerisationsfähige derivate von polyamiden
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP0991940B1 (de) 1997-06-18 2010-08-25 Merck Patent GmbH Verwendung monolithischer sorbentien für präparative chromatographische trennverfahren
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
FR2824568B1 (fr) * 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
WO2003059935A2 (en) * 2001-12-21 2003-07-24 Immunex Corporation Methods for purifying protein
AU2006223180B2 (en) * 2005-03-11 2011-11-24 Wyeth Llc A method of weak partitioning chromatography
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
ES2538986T3 (es) * 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
AU2009347206C1 (en) * 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
CA2808116C (en) * 2010-07-30 2016-06-07 Pfizer Inc. Tandem purification of proteins
WO2012176158A1 (en) 2011-06-24 2012-12-27 Dr. Reddy's Laboratories Limited Purification of chimeric protein
BR112014000352A2 (pt) * 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
CA2854233C (en) * 2011-11-04 2020-05-12 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
SG10201701224UA (en) * 2012-03-12 2017-04-27 Merck Patent Gmbh Removal of protein aggregates from biopharmaceutical preparations in a flowthrough mode
EP3395423B1 (en) * 2013-03-14 2023-09-20 Amgen Inc. Removal of leaked affinity purification ligand

Also Published As

Publication number Publication date
ES2674697T5 (es) 2022-04-19
EP3395423B1 (en) 2023-09-20
HUE064450T2 (hu) 2024-03-28
PL3395423T3 (pl) 2024-03-18
HK1220159A1 (en) 2017-04-28
DK3395423T3 (da) 2023-11-20
JP2016513643A (ja) 2016-05-16
LT2969099T (lt) 2018-09-10
US20220144886A1 (en) 2022-05-12
SI3395423T1 (sl) 2023-12-29
TR201809050T4 (tr) 2018-07-23
DK2969099T4 (da) 2022-03-14
JP6457479B2 (ja) 2019-01-23
WO2014159441A1 (en) 2014-10-02
US20160024144A1 (en) 2016-01-28
CY1120353T1 (el) 2019-07-10
EP2969099A1 (en) 2016-01-20
EP2969099B1 (en) 2018-04-25
PT3395423T (pt) 2023-11-14
US20190085021A1 (en) 2019-03-21
EP3395423A1 (en) 2018-10-31
CA2904411A1 (en) 2014-10-02
LT3395423T (lt) 2023-12-11
PT2969099T (pt) 2018-07-05
HUE038565T2 (hu) 2018-10-29
MX2015011994A (es) 2015-12-01
DK2969099T3 (en) 2018-07-09
US11492372B2 (en) 2022-11-08
ES2964601T3 (es) 2024-04-08
AU2014240596B2 (en) 2018-09-27
PL2969099T3 (pl) 2018-10-31
EP4026596A1 (en) 2022-07-13
SI2969099T2 (sl) 2022-04-29
EP2969099B2 (en) 2021-12-22
MX2019006568A (es) 2019-08-22
AU2014240596A1 (en) 2015-09-24
ES2674697T3 (es) 2018-07-03
MX391507B (es) 2025-03-21
MX365501B (es) 2019-06-05
PL2969099T5 (pl) 2022-06-13
SI2969099T1 (sl) 2018-09-28
US11192919B2 (en) 2021-12-07

Similar Documents

Publication Publication Date Title
FI3395423T3 (fi) Vuotaneen affiniteettipuhdistusligandin poistaminen
JP2015042645A5 (https=)
JP2016513643A5 (https=)
CY1116129T1 (el) Καθαρισμος αντισωματος με κατιονανταλλακτικη χρωματογραφια
BRPI0611600B8 (pt) método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
MX395730B (es) Uso de lavados alcalinos durante la cromatografia para remover impurezas.
RU2012130151A (ru) Промывочный раствор и способ промывки для аффинной хроматографии
SE0400501D0 (sv) Antibody purification
RU2014111820A (ru) Способы элиминации вируса
EA201592192A1 (ru) Способ очистки моноклональных антител
JP2014500311A5 (https=)
AR062711A1 (es) Lavado de arginina en l a purificacion de proteinas usando cromatografia de afinidad
JP2016530533A5 (https=)
JP2017521389A5 (https=)
ATE547521T1 (de) Verfahren zur reinigung von nukleinsäure
FI3912987T3 (fi) Puhdistusalusta bispesifisille vasta-aineille
RU2017101727A (ru) Способы и реагенты для очистки белков
WO2013096322A8 (en) Ion exchange membrane chromatography
RU2019109975A (ru) Способы очистки антител
JP2012503170A5 (https=)
JP2017510305A5 (https=)
JP2014507368A5 (https=)
EP4671270A3 (en) Method for purifying antibody having low isoelectric point
Westra et al. Immobilised metal-ion affinity chromatography purification of histidine-tagged recombinant proteins: a wash step with a low concentration of EDTA